Treatment News : Thalidomide for HIV-Related IRIS Shows Promise

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 21, 2012

Thalidomide for HIV-Related IRIS Shows Promise

Thalidomide, a historically controversial drug, may hold potential for people living with HIV who experience immune reconstitution inflammatory syndrome (IRIS) and do not respond favorably and quickly to corticosteroids like prednisone, according to a small series of case reports published online ahead of print by the journal AIDS.

Thalidomide, banned globally after more than 10,000 children were born with deformities after being exposed to the drug in utero during the late 1950s and early 1960s, is now used—with strict controls to prevent birth defects—to treat multiple myeloma and leprosy. It has also been used to manage wasting syndrome and oral ulcers in people living with HIV.

A team of French researchers now report that the drug may hold promise for “paradoxical IRIS”—worsening of various AIDS-related infection symptoms after beginning antiretroviral (ARV) therapy. The researchers detail the experiences of three patients, two with recurrent symptoms of cryptococcal meningitis and one with tuberculosis-related kidney disease, after they started ARV treatment with very low CD4 cell counts and were otherwise responding well to treatment. 

It wasn’t until 100 milligrams (mg) of thalidomide was started that they were able to successfully stop antibiotic and corticosteroid therapy for their symptoms.

"In our cases, clinical responses were rapid under thalidomide and cortisone therapy and were maintained after tapering of corticosteroids,” the authors note, “arguing for a direct and strong anti-inflammatory effect of thalidomide. The drug was also well tolerated at low doses, with only mild dizziness and constipation reported in two subjects.”

They conclude: “Thalidomide may be an interesting salvage treatment in patients with cortico-dependent or refractory IRIS, and should be further studied in clinical trials.”

To read the AIDS case reports (paid subscription required), click here.

Search: thalidomide, immune reconstitution inflammatory syndome, iris, france, meningitis, pneumonia, corticosteroids, prednisone


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    chrisf
    san jose
    California


    Loveladyd
    Washington
    DC


    TaintedloveDC
    Washington
    DC


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.